Trump Says Anthropic No Longer Seen as National Security Threat 
Meta Seeks Legal Shield From Child-Harm Lawsuits Amid KOSA Talks 
Oracle Cuts 21,000 Jobs as AI Reshapes Workforce and Cloud Expansion Accelerates 
US-Iran De-Escalation Shifts Washington’s Focus to AI Regulation and Crypto Legislation 
Google’s Open-Source AI Data Center Cooling Design Raises Commoditization Concerns 
Nissan Halts Electric Qashqai Development Amid EV Market Challenges 
Qualcomm Nears $4 Billion Acquisition of AI Chip Startup Modular 
WiseTech Global Denies Knowledge of Investigation Into Founder Richard White 
Trump’s Quantum Push Lifts IBM Stock as CEO Arvind Krishna Receives White House Praise 
JPMorgan Sees Strong Strategic Value in Potential AbbVie Acquisition of Apogee Therapeutics 
Apollo Debt Solutions Limits Redemptions as Withdrawal Requests Surge 
TD Bank Expands Employee Monitoring Software to Boost Productivity Amid Privacy Concerns 
Tencent Reviews Marvelous Stake as Gaming Giant Reassesses Global Investment Strategy 
John Jumper Leaves Google DeepMind for Anthropic Amid Intensifying AI Talent Race 
Ukrainian Drone Makers Target Japan and Asia Defense Market 
California Drivers Sue BP, Walmart, 7-Eleven Over Alleged AI Gas Price Fixing 
EMERYVILLE, Calif., Feb. 03, 2016 -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing therapies for the treatment of central nervous system (CNS) disorders, today announced that Stephen J. Farr, Ph.D., President and CEO, and Bradley S. Galer, M.D., Executive Vice President and CMO, will present a corporate update at the LEERINK Partners 5th Annual Global Healthcare Conference in New York, NY, on February 10, 2016.
| LEERINK Partners 5th Annual Global Healthcare Conference -- Zogenix Presentation Details | |
| Date: | Wednesday, February 10, 2016 |
| Time: | 10:40 am Eastern Time / 7:40 am Pacific Time |
| Location: | New York, NY - The Waldorf Astoria Hotel, Metropolitan Suite |
The presentation will be webcast live and archived for 30 days on Zogenix's Investor Relations website at ir.zogenix.com.
About Zogenix
Zogenix, Inc. (Nasdaq:ZGNX) is a pharmaceutical company committed to developing and commercializing CNS therapies that address specific clinical needs for people living with orphan and other CNS disorders who need innovative treatment alternatives to improve their daily functioning.
For more information, visit www.zogenix.com.
CONTACT: Investors: Andrew McDonald Founding Partner, LifeSci Advisors LLC 646-597-6987 | [email protected]
